SCHEMBL24418337

SCHEMBL24418337

COC(=O)c1cccc(C(=O)CCCCCCCNC(=O)OC(C)(C)C)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.49
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
SUCNR1 Q9BXA5 3/20 0.43
DRD2 P14416 3/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
BCHE P06276 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
BRD4 O60885 1/20 0.42
TPSAB1 Q15661 1/20 0.42
TPSD1 Q9BZJ3 1/20 0.42
TPSG1 Q9NRR2 1/20 0.42
CES1 P23141 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25937836 0.86 CYP3A4 (0.49) CYP3A4TDP1KDM4ENPC1MAPT
SCHEMBL29672768 0.82 MEN1 (0.46) CYP3A4TDP1MAPTSUCNR1DRD2
SCHEMBL24418340 0.82 MEN1 (0.46) CYP3A4TDP1MAPTSUCNR1DRD2
SCHEMBL23469615 0.80 TDP1 (0.41) CYP3A4TDP1KDM4ENPC1MAPT
SCHEMBL39993 0.80 CYP3A4 (0.52) CYP3A4TDP1KDM4ECA12CA1
SCHEMBL24418750 0.80 SUCNR1 (0.45) SUCNR1DRD2CA12CA1CA2
SCHEMBL29672755 0.80 SUCNR1 (0.45) SUCNR1DRD2CA12CA1CA2
SCHEMBL24418319 0.79 SUCNR1 (0.44) CYP3A4TDP1MAPTSUCNR1DRD2
SCHEMBL29672783 0.79 SUCNR1 (0.44) CYP3A4TDP1MAPTSUCNR1DRD2
SCHEMBL29316553 0.79 MAPT (0.49) CYP3A4NPC1MAPTRAB9ACES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238461-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF JANSSEN BIOTECH, INC. 2024-07-18 US disclosed
WO-2023144723-A1 IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES JANSSEN BIOTECH, INC. (US) 2023-08-03 WO disclosed
US-20220143231-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF JANSSEN BIOTECH, INC. 2022-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143231-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF BDNF, CD47, MAG CYP3A4 2411/4885TDP1 1821/4885KDM4E 1726/4885
US-20240238461-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF BDNF, CD47, MAG CYP3A4 2411/4885TDP1 1821/4885KDM4E 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.